Q2 2026 Financial Results Call
The Company’s management will host a Zoom conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time.
To join the conference, please register in advance.
Sitemap
Pages
- Accessibility Statement
- Careers
- Company
- Contact Us
- Home
- Investor Relations
- Investor Relations – Old just for save
- Market Segments
- Newsroom
- Privacy Policy
- Sitemap
- Solutions
- Subsidiaries & Partners
- Terms of Use
- test
Posts by category
- Category: News
Careers
Press releases
- Evogene Schedules Second Quarter 2026 Financial Results Release
- Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases
- AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities
- Evogene and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
- Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization
- Evogene to Present Its Pharma Division Achievements at the BIO International Convention
- Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
- Evogene Reports First Quarter 2026 Financial Results
- Evogene to Present at the 24th Schrödinger European User Group Meeting
- Evogene Schedules First Quarter 2026 Financial Results Release
- Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock
- Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026
- Evogene Reports Fourth Quarter and Full Year 2025 Financial Results
- Evogene Releases CEO Letter to Shareholders
- Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release
- Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics
- Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases
- Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds
- Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™
- Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board
- Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
- Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders
- Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development
- Evogene Reports Third Quarter 2025 Financial Results
- Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming
- Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York
- Evogene Reports Second Quarter 2025 Financial Results
- Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases
- Evogene Schedules Second Quarter 2025 Financial Results Release
- Evogene Announces Completion of Transaction for the Sale of Lavie Bio’s Activity to ICL
- Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud
- Evogene Reports First Quarter 2025 Financial Results
- Evogene Schedules First Quarter 2025 Financial Results Release
- ICL to Acquire the Activity of Evogene’s subsidiary, Lavie Bio
- Evogene Reports Fourth Quarter and Full Year 2024 Financial Results
- Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025
- Evogene Schedules Fourth Quarter 2024 Financial Results Release
- AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease
- Evogene Reports Third Quarter 2024 Financial Results
- Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results
- Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials
- Evogene Schedules Third Quarter 2024 Financial Results Release
- Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design
- Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya
- Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
- Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of ‘MicroFermentor’, a Unique Technology that Can Change the Economics of Ag-Biologicals
- Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
- Evogene Reports Second Quarter 2024 Financial Results
- Evogene Schedules Second Quarter 2024 Financial Results Release
- Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
- Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil
- Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
- ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants
- Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat
- Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country
- Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
- Evogene Reports First Quarter 2024 Financial Results
- Casterra Announces Additional Agreements with Seed Producers to Meet Existing & Growing Demand for its Elite Castor Seeds
- Evogene Schedules First Quarter 2024 Financial Results Release
- Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
- Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
- Evogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry
- Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
- Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing
- Lavie Bio and Ceres Global Ag Corp. Collaborate to Include YalosTM Bio-Inoculant, in Regenerative Agriculture Initiatives in North America
- Evogene Reports Fourth Quarter and Full Year 2023 Financial Results
- AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides
- Casterra Announces New Agreements with Seed Producers in Brazil and Africa to Meet Growing Demand for its Elite Castor Seed Varieties
- Lavie Bio Successfully Secures Second Half Advance Payment of $2.5M after Meeting Corteva's Licensing Agreement Requirements
- Evogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024
- AgPlenus Announces Appointment of Dr. Dan Jacob Gelvan as its Incoming Chief Executive Officer
- AgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control Solution
- Syngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-Insecticide
- Evogene and Verb Biotics Enter Collaboration Agreement to Advance Probiotic Innovation
- Biomica CEO Set to Engage in Panel Discussion at 8th Annual European Microbiome Movement Summit
- Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug
- Biomica CEO Set to Attend JP Morgan Healthcare Week in San Francisco, January 8-11, 2024
- Casterra Appoints New CEO and Expands Team to Drive Growth and Innovation
- Lavie Bio Announces a Distribution Agreement with WinField United Canada for its Bio-Inoculant Seed Treatment YalosTM
- Lavie Bio Announces Expansion of its Bio-Inoculant Product for Spring Wheat, Yalos™, to Durum and Barley
- Evogene Reports Third Quarter 2023 Financial Results
- Lavie Bio Reports Advancement in Bio-Fungicide Program Against Downy Mildew with 2023 Field Trial Results
- Evogene Schedules Third Quarter 2023 Financial Results Release & Conference Call for November 15, 2023
- Colors Farm, Evogene and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology
- Evogene Provides Operational Update Amidst Current Security Situation in Israel
- Casterra Delivers First Shipment of Castor Seeds to Africa
- Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
- Evogene Reports Second Quarter 2023 Financial Results
- Biomica Opens Second Site to Advance Its Immuno-Oncology Drug Trials at Davidoff Center
- Evogene Schedules Second Quarter 2023 Financial Results Release & Conference Call for August 17, 2023
- Evogene's ChemPass AI Tech-Engine is Introduced with New Breakthrough Machine Learning Technology for Target-Protein Discovery
- Biomica Announces Interim Positive Results from Pre-Clinical Studies in its Irritable Bowel Syndrome (IBS) Program
- Evogene Announces Pricing of US$8,500,000 Registered Direct Offering
- Lavie Bio Announces Licensing Agreement for Bio-Fungicides with Corteva Agriscience
- AgPlenus Appoints Dr. Adrian Percy to Its Board of Directors
- Casterra Announces Additional $2.2 Million of Purchase Orders to Supply Castor Seeds for New African Territories
- Casterra Signs a Framework Agreement with a World Leading Oil and Gas Company to Sell Its Castor Seeds for Sustainable Biofuel Production, with Initial Purchase Orders of $9.1 Million
- Lavie Bio Receives Canadian Regulatory Approval for ThrivusTM, Expanding Global Reach
- Evogene Reports First Quarter 2023 Financial Results
- Evogene Ag-Seed Division Awarded Prestigious €1.2M Horizon Grant to Develop Oil-Seed Crops with High CO2 Assimilation & Drought Tolerance
- Evogene Schedules First Quarter 2023 Financial Results Release & Conference Call for May 18, 2023
- Plantis Licenses Two of Canonic's Proprietary Cannabis Varieties to Expand its Offerings in the Israeli Market
- Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital
- Evogene Announces Filing of Annual Report on Form 20-F
- Lavie Bio Announces Appointment of Amit Noam as its Incoming Chief Executive Officer
- Evogene Reports Fourth Quarter and Full Year 2022 Financial Results
- Evogene to Attend the Annual ROTH Investor Conference in California on March 13, 2023
- Lavie Bio Reports Successful Results for its Bio-Fungicides Programs
- Evogene Schedules Fourth Quarter and Full Year 2022 Financial Results Release & Conference Call for March 9, 2023
- Canonic Successfully Launched Six Second-Generation Cannabis Products with Higher THC and Rich Terpene Profiles
- Biomica CEO to Participate in Panel Discussion at 7th European Annual Microbiome Movement
- Casterra Announces Agreement with World Leading Energy Company to Cultivate its Castor Varieties at Commercial Scale
- Biomica CEO to Attend the JP Morgan Healthcare Week in San Francisco between January 9-11, 2023
- Biomica Raises $20 Million in a Financing Round to Advance its Pipeline of Microbiome-based Therapeutics
- Evogene to Receive $3.5 million Payment Related to Patent Portfolio under its Existing Seed Traits Collaboration with Bayer
- Evogene Reports Third Quarter 2022 Financial Results
- Casterra Signs Royalty Agreement with Titan for Castor Oil Sales in South-Eastern Africa
- Biomica CEO to Participate in an Industry Panel Discussion at Microbiome Connect USA 2022 Summit
- Evogene Schedules Third Quarter of 2022 Financial Results Release & Conference Call for November 17, 2022
- Lavie Bio Advances its Novel Bio-fungicide Program and Applies to the U.S. EPA for Regulatory Approval
- Evogene to Present at the LD Micro Main Event XV Investor Conference in Los Angeles
- Canonic Launches its Second-Generation Medical Cannabis Products with High THC and Unique Terpene Profiles
- Lavie Bio Announces Appointment of Guri Oron as CEO
- Canonic Advances its Penetration into Europe by Signing its First Licensing Agreement with GroVida
- Evogene to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- Evogene Reports Second Quarter 2022 Financial Results
- Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
- ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products
- Evogene Financial Results and Earnings Announcement Schedule for the Second Quarter of 2022
- Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug
- Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug
- Biomica to Present at the Microbiome Connect Europe 2022
- Biomica to Present at the 7th Microbiome Movement Drug Development Summit
- Evogene Reports First Quarter 2022 Financial Results
- Biomica to Present at the ASCO 2022 Annual Meeting
- Biomica to Present at the 2022 Digestive Disease Week (DDW) Conference
- Lavie Bio Announces Successful Product Launch of its Bio-Inoculant result™ for the 2022 Spring Wheat Growing Season
- Evogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2022
- Biomica Announces Agreement with Sheba Medical Center for Joint Microbiome Clinical Research
- Evogene to Present at the Jefferies Virtual Synthetic Biology Week on March 23, 2022
- Evogene Reports Fourth Quarter and Full Year 2021 Financial Results
- Evogene to Attend to World Agri-Tech Innovation Summit from March 22-23, 2022
- Evogene to Attend the 34th Annual ROTH Investor Conference in Dana Point California Between March 13-15, 2022
- Canonic Announces Professor Itamar Grotto Joining its Board of Directors
- Evogene Financial Results and Earnings Announcement Schedule for the Full Year and Fourth Quarter of 2021
- Evogene to Present at Aegis Virtual Conference
- Canonic Announces Shipment of its Cannabis Varieties to Europe
- Evogene to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
- Canonic Announces Positive Results in Pre-Clinical Studies in its Precise Product Program for Medical Cannabis
- Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb’s Anti-PD-1 Opdivo®
- Lavie Bio Reports Advancement in its Bio-Fungicide Program for Fruit Rots
- Biomica Reports Positive Results from Pre-Clinical Studies in its Inflammatory Bowel Disease (IBD) Program
- Evogene Reports Third Quarter 2021 Financial Results
- Evogene Announces Participation in the Second Research Period of the CRISPR-IL Consortium
- Lavie Bio Announces Commercial Launch of its First Microbiome-Based Product for Yield Improvement - result™
- Biomica & Rambam Health Care Campus Sign Agreement for Clinical Trial of Biomica’s Microbiome-Based Immuno-Oncology Drug
- Evogene Financial Results and Earnings Announcement Schedule for the Third Quarter of 2021
- Canonic Announces Full Commercial Launch of its First Medical Cannabis Products in Israel
- Lavie Bio and United Agronomy Announce Signing of Distribution Agreement for Lavie Bio’s Inoculant Product
- Evogene to Present at Cantor Virtual Global Healthcare Conference, September 2021
- Evogene to Present at H.C. Wainwright 23rd Annual Global Investment Conference - 2021
- Canonic Announces Pre-Launch of its First Generation Medical Cannabis Products in Israel
- Evogene Reports Second Quarter 2021 Financial Results
- Evogene to Present at Jefferies Virtual Industrials Conference, 2021
- Evogene Financial Results and Earnings Announcement Schedule for the Second Quarter of 2021
- AgPlenus Announces Positive Results for a Herbicide Resistance Trait to its Leading Herbicide Product Candidate
- Evogene Announces Ms. Sarit Firon to become Evogene's Chairperson of the Board
- Evogene Reports First Quarter 2021 Financial Results
- Lavie Bio Announces the Appointment of Russ Putland as Vice President Commercial
- Evogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2021
- Biomica To Present at Jefferies Microbiome-Based Therapeutics Summit, on April 22nd, 2021 (Virtual Conference)
- Biomica Announces Positive Pre-Clinical Results, Demonstrating Efficacy of BMC128 in Melanoma
- Evogene to Hold Virtual Investor & Analyst Days
- Evogene Files Annual Report for the Year Ended December 31, 2020
- Canonic of Evogene Group and Tikun Olam (Israel)-Cannbit, sign production and distribution agreements for Canonic products in Israel
- Plastomics and Evogene’s Ag-Seed division enter a collaborative agreement targeting novel insect control traits for soybean
- Evogene Reports Fourth Quarter and Full Year 2020 Financial Results
- Cannbit, subsidiary of Tikun Olam-Cannbit, and Canonic of Evogene group announce collaboration for the development of novel medical cannabis products
- Evogene Financial Results and Earnings Announcement Schedule for the Fourth Quarter and Full Year of 2020
- Biomica Announces Participation at the Crohn’s & Colitis Congress® January 21-24, 2021 (Virtual Conference)
- Biomica Announces Participation at the 5th Microbiome Movement Drug Development Europe Conference on January 28-29, 2021 (Virtual Conference)
- Evogene Provides 2020 Year-End Update for CRISPR-IL Consortium
- Lavie Bio Provides Product Pipeline Update for 2020
- Canonic Announces Signing of First Cultivation Agreement for its Medical Cannabis Varieties
- AgPlenus Announces Reaching a ‘Lead’ Stage in its Novel Mode-of-Action Herbicide Program
- Evogene Reports Third Quarter 2020 Financial Results
- Canonic Received Approval for Propagation of Medical Cannabis from the Israel Medical Cannabis Agency
- Evogene Announces Closing of $12 Million Registered Direct Offering
- Evogene Financial Results and Earnings Announcement Schedule for the Third Quarter of 2020
- Evogene Prices $12 Million Registered Direct Offering
- Lavie Bio Announces Positive Results for LAV311 and LAV312 in its Bio-Fungicide Program
- Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program
- Biomica Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)
- Evogene Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)
- Biomica Announces Positive Pre-Clinical Results in its Immuno-Oncology Program
- Evogene Announces $10 Million Equity Investment led by ARK Investment Management, LLC
- Evogene to Present at LD 500 Virtual Conference
- Evogene Reports Second Quarter 2020 Financial Results
- Evogene to Present at Jefferies Virtual 2020 Industrials Conference
- Evogene Financial Results and Earnings Announcement Schedule for the Second Quarter of 2020
- Evogene to Participate in CRISPR-IL Consortium to Provide end-to-end Artificial Intelligence System for Genome-Editing
- Evogene Reports First Quarter 2020 Financial Results
- Evogene Launches its New Branding to Reflect the Company's Expanded Vision and New Business Model
- Evogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2020
- מכתב לבעלי מניות
- Letter to Shareholders
- Evogene Files Annual Report for the Year Ended December 31, 2019
- Corteva Agriscience and AgPlenus Announce Collaboration for the Development of Novel Herbicides
- Evogene Reports Fourth Quarter and Full Year 2019 Financial Results
- Evogene to Attend in Bank of America 2020 Global Agriculture and Materials Conference
- Evogene Financial Results for the Fourth Quarter and Full Year of 2019 Earnings Announcement Schedule
- Canonic Announces an Agreement with Hadassah Medical Center for Pre-Clinical Studies to Support the Development of Canonic’s Medical Cannabis Products
- Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program
- Lavie Bio Announces Advancement in its Product Development Pipeline for Wheat Bio-Stimulants
- Evogene Reports Third Quarter 2019 Financial Results
- Biomica Reports Positive Preliminary Results in Animal Studies in its Immuno-Oncology Program
- Canonic Announces Initiation of Cultivation and Breeding of Cannabis Varieties with Unique Genomic Profiles for the Development of Medical Cannabis Products
- Biomica To Collaborate with Weizmann Institute of Science to Develop A Selective Treatment Against Antibiotic Resistant Bacteria
- Evogene Financial Results for the Third Quarter of 2019 Earnings Announcement Schedule
- Biomica Announces Advancement to Pre-Clinical Studies in its Inflammatory Bowel Disease Program
- Lavie Bio, Evogene’s Ag-Biologicals Subsidiary, Announces the Nomination of Industry Experts to its Board of Directors
- Canonic to Present at CannX, 4th International Medical Cannabis Conference in Tel Aviv
- Corteva Agriscience to Invest in Evogene’s Agriculture Biologicals Subsidiary, Lavie Bio
- Evogene Reports Second Quarter of 2019 Financial Results
- Evogene Amends its Collaboration Agreement with Bayer to Include Genome Editing Targets
- Evogene to Present at Jefferies 2019 Industrials Conference
- Evogene Financial Results for the Second Quarter of 2019 Earnings Announcement Schedule
- Lavie Bio Announces Positive 2nd Year Field Results in its Bio-Stimulant Program for Wheat
- Evogene Reports First Quarter of 2019 Financial Results
- Evofuel to participate in the 2019 International Castor Oil Association – ICOA Conference
- Evogene Financial Results for the First Quarter of 2019 Earnings Announcement Schedule
- Biomica Initiates Pre-Clinical Studies in its Immuno-Oncology Program
- Evogene to Develop Next Generation Medical Cannabis Products through New Subsidiary - Canonic Ltd
- AgPlenus - Evogene’s Ag-Chemicals Subsidiary - Announces the Nomination of Three Industry Leaders from the Field of Crop Protection to its Board of Directors
- Evogene to Participate in the World Agritech, Innovation Summit in San Francisco in March 19-20, 2019
- Evogene Reports Fourth Quarter and Full Year 2018 Financial Results
- Letter to Shareholders
- Evogene Fourth Quarter and Full Year of 2018 Earnings Announcement Schedule
- Evogene Announces Establishment of Ag-Biologicals Subsidiary – LaVie Bio Ltd.
- Evogene Appoints Dr. Adrian Percy to its Board of Directors
- Evogene and TMG Announce Collaboration to Develop Nematode Resistant Soybean through Genome Editing
- Evogene’s Leading Insect Control Genes Demonstrate Effectiveness Against Insects with Resistance to Current Commercial Solutions
- AgPlenus, a subsidiary of Evogene, to Present at the 2nd Annual AgChem & Technology Europe Conference
- Evogene Announces Establishment of Ag-Chemicals Subsidiary – AgPlenus Ltd.
- Evogene Reports Third Quarter 2018 Financial Results
- Biomica Announces the Addition of Internationally Renowned Experts in the Fields of Gastroenterology and the Human Microbiome to its Scientific Advisory Board
- Evofuel and Fantini s.r.l Announce Breakthrough in Mechanical Harvesting for Castor Bean
- Evogene Financial Results for the Third Quarter of 2018 Earnings Announcement Schedule
- Evogene Announces a Significant Milestone in its Next Generation Herbicide Pipeline
- Evogene Reports Second Quarter 2018 Financial Results
- Evogene Financial Results for the Second Quarter of 2018 Earnings Announcement Schedule
- Evogene and IMAmt Enter a Collaboration in the Field of Insect Resistance Traits in Cotton
- Evogene Announces Positive Yield Results in its Bio-Stimulant Program for Wheat
- Evogene Reports First Quarter 2018 Financial Results
- BASF and Evogene announce multiyear collaboration for the development of novel insecticides
- Biomica Announces Participation in the Microbiome Invest Conference in London May 23, 2018
- Evogene Financial Results for the First Quarter of 2018 Earnings Announcement Schedule
- Evogene and Marrone Bio Innovations Announce Phase Advancement in their Insect Control Collaboration
- Biomica, Evogene’s Newly Established Subsidiary, Announces Therapeutic Areas of Focus
- Evogene Files Annual Report for the Year Ended December 31, 2017
- Evogene Reports Fourth Quarter and Full Year 2017 Financial Results
- מכתב מנכ"ל אבוג'ן לבעלי המניות
- CEO Letter to Shareholders
- Evogene Announces Positive Results in its Novel Mode-of-Action Herbicide Program
- Evogene Financial Results for the Fourth Quarter and Full Year 2017 Earnings Announcement Schedule
- Evogene to Participate in Israeli Consortium to Develop Phenotyping Tools and Systems for Precision Agriculture
- Evogene Announces Positive 2nd Year Field Trial Results in Corn Bio-Stimulant Ag-Biologicals Program
- Evogene Reports Third Quarter 2017 Financial Results
- Evogene Financial Results for the Third Quarter of 2017 Earnings Announcement Schedule
- Evogene Announces Revised and Expanded Market Focus and New Corporate Structure
- Evogene & Rahan Meristem announce positive results in 2nd year field trials addressing Black Sigatoka disease in banana and the utilization of the results for genome editing
- Evogene to Present at the 26th Asian-Pacific Weed Science Society Conference
- Evogene Reports Second Quarter 2017 Financial Results
- DuPont Pioneer & Evogene Announce Multiyear Research Collaboration for Development of Corn Bio-Stimulant Products
- Evogene Financial Results for the Second Quarter of 2017 Earnings Announcement Schedule
- Evogene Achieves Important Milestone in Monsanto Crop Disease Collaboration
- Evogene announces positive results in Insect Control Seed Trait Program and advancement to Phase-I of first toxin against Western corn rootworm
- Evogene Reports First Quarter 2017 Financial Results
- Evogene Financial Results for the First Quarter of 2017 Earnings Announcement Schedule
- Marrone Bio Innovations and Evogene Advance Novel Bacteria and Related Proteins Beyond Discovery into Insecticidal Product Development Phase
- Evogene to Present Innovative Approach for Improving Cannabis for Medical Needs at CannaTech Summit
- Evogene Reports Fourth Quarter and Full Year 2016 Financial Results
- Evogene and ICL Innovation Sign Collaboration for Development of Crop Enhancers
- Evogene Fourth Quarter and Full Year 2016 Earnings Announcement Schedule
- Evogene to Transfer Stock Exchange Listing to Nasdaq
- Evogene Reports Third Quarter 2016 Financial Results
- Evogene Announces Positive Field Trial Results in Ag-biologicals Program
- Evogene Third Quarter 2016 Earnings Announcement Schedule
- Evogene and IMAmt Sign Collaboration for Genomic Promoter Discovery and Validation in Cotton
- Evogene Announces Joint Microbial Diversity Activity with University of Missouri
- Evogene Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
- Evogene Reports Second Quarter 2016 Financial Results
- Evogene to Participate at Piper Jaffray Global Agriculture Symposium
- Evogene Second Quarter 2016 Earnings Announcement Schedule
- Evogene Appoints a New Member to Board of Directors and a New Chief Operating Officer
- Evogene to Present at Crops and Chemicals 2016 Conference
- Evogene Reports Financial Results for the First Quarter of 2016
- Evogene and Marrone Bio Innovations Disclose Positive Results in Insect Control Collaboration
- Evogene to Present the Potential of Integrating Novel Genome Editing Technology with its Core Capabilities for Improved Seed Traits at Plant Genomics Congress
- Evogene’s First Quarter 2016 Earnings Announcement Schedule
- Evogene Files Annual Report for the Year Ended December 31, 2015
- Evogene Selected for Photosynthesis Research Consortium within European Horizon 2020 Program
- Evogene Reports Fourth Quarter and Full Year 2015 Financial Results
- Evogene Discloses Positive Results in Yield Improvement Collaboration with Monsanto Utilizing Novel 'Trait-First' Methodology
- Evogenes Fourth Quarter with Full Year 2015 Earnings Announcement Schedule
- Evogene Appoints Eyal Leibovitz as Chief Financial Officer
- BASF and Evogene Sign Collaboration Agreement for Novel Herbicide Discovery and Development
- Evogene Officially Opens Research and Development Facility in St. Louis, Missouri
- Evogene Reports Third Quarter 2015 Financial Results
- Evogene’s Third Quarter 2015 Earnings Announcement Schedule
- Evogene to Present at Credit Suisse Annual Basic Materials Conference
- Evogene to Establish Validation Capabilities for Soybean Cyst Nematodes
- Evogene to Present at Jefferies 2015 Industrials Conference
- Evogene Reports Second Quarter 2015 Financial Results
- Evogene Announces Successful Completion of First Computational Discovery of Novel Microbial Genes for Insect Control
- Evogene to Participate at Piper Jaffray Technology-Enabled Industrials Symposium
- Evogene Announces Discovery and Validation of Novel Plant Targets for Herbicides
- Evogene’s Second Quarter 2015 Earnings Announcement Schedule
- Evogene to Present at LD Micro Invitational
- Evogene Reports First Quarter 2015 Financial Results
- Evogene Files Annual Report for the Year Ended December 31, 2014
- Evogene’s First Quarter 2015 Earnings Announcement Schedule
- Evogene CEO Ofer Haviv and Marrone Bio Innovations CEO Pam Marrone to Participate in ‘Profiling Tomorrow’s Ag Solutions’ Panel Discussion at AgriVest 2015
- Evogene Discloses First Collaboration with Leading Multinational Food Company for Improving Crop Productivity
- Evogene Reports Fourth Quarter and Full Year 2014 Financial Results
- Evogene Introduces Biology Driven Ag-Chemical Discovery Platform
- Evofuel Expands Castor Activity in Brazil with Insolo
- Evogene to Establish Research and Development Facility in the United States
- Evogene’s Fourth Quarter and Full Year 2014 Earnings Announcement Schedule
- Evogene New Gene Optimization Program Being Incorporated into Yield & Environmental Stress Collaboration with Monsanto
- CNH Industrial and Evogene Subsidiary Announce Ongoing Collaboration for the Development of a Mechanized Harvesting Solution for Castor Beans
- Evogene Reports Third Quarter 2014 Financial Results
- Evogene Announces Expansion of Crop Protection Activities
- Evogene’s Third Quarter 2014 Earnings Announcement Schedule
- Evogene Subsidiary and Embrapa to Cooperate on Advancing Castor Cultivation in Brazil
- Evogene Reports Second Quarter 2014 Financial Results
- Evogene to Present at Credit Suisse 2014 Basic Materials Conference
- Evogene to Present at Jefferies 2014 Global Industrials Conference
- Evogene’s Second Quarter 2014 Earnings Announcement Schedule
- Evogene Announces Amendment to Bayer Wheat Agreement to Focus on Discovery of Novel Genomic Promoters
- Evogene and Marrone Bio Innovations Sign Multi-Year Collaborative Agreement
- Evogene Reports First Quarter 2014 Financial Results
- Evogene Enters the Field of Insect Resistance
- Evogene’s First Quarter 2014 Earnings Announcement Schedule
- Evogene Announces Filing of 2013 Annual Report
- Evogene Subsidiary and SLC Agricola Sign Collaboration Agreement for Commercial Production of Castor Bean in Brazil
- Evogene Reports Fourth Quarter and Year-End 2013 Financial Results
- Evogene Enhances Predictive Gene Stacking Capabilities
- Evogene Announces Closing of its Initial Public Offering in the United States and Full-Exercise of Over-Allotment Option
- Evogene Prices Its Initial Public Offering in the United States
- Monsanto and Evogene Extend and Expand Collaboration for Crop Improvement
- Evogene Reports Third Quarter 2013 Financial Results
- Evogene and DuPont Pioneer Expand Collaboration For Soybean Rust Resistance
- Evogene Files Registration Statement for Proposed Initial Public Offering in the United States
- Syngenta and Evogene Extend Soybean Nematode Resistance Collaboration
- Evogene Subsidiary Completes Three Years of Successful Field Trials for Improved Castor Seeds
- Evogene Reports Second Quarter and First Half 2013 Financial Results
- Evogene and Rahan Announce Successful Field Trial Results For Black Sigatoka Resistance in Bananas
- Evogene Appoints Two New Members to Board of Directors
- Evogene Hosts President of the State of Israel, Mr. Shimon Peres
- Evogene to Collaborate with Chinese Biotechnology Company DBN on Improving Key Rice Traits
- Evogene Reports First Quarter 2013 Financial Results
- Evogene Announces Appointment of Chief Financial Officer
- Evogene Reports Fourth Quarter and Year End 2012 Financial Results
- Evogene Announces Launch of Model Plant Validation System for Monocot Plants
- Evogene Announces Launch of Gene2Product™ Computational AgBio Platform
- Evogene Reports First Quarter 2012 Financial Results
- Evogene Announces Launch of ATHLETE™ 4.0 Gene Discovery Computational Technology
- Evogene Expands Research and Development Facilities by Over 50%
- Evogene Reports Fourth Quarter and Year End 2011 Financial Results
- Evogene's New Recruitments Expand Its Scientific Team
- Evogene to Establish Evofuel Ltd. for Developing Advanced Feedstock for Biofuel
In the media
- Talking HealthTech - BIO International Convention 2026
- The Jerusalem Post
- Pharmaphorum Podcast: Conversation with Dr. Olga Nissan, VP Business Development at Evogene, Recorded at BIO-Europe Spring
- 'In Vivo BioBytes' article on Citeline, featured the integration of AI agents into Evogene's ChemPass AI using Google Cloud Vertex AI
- Pharmaceutical-technology: Evogene and QUT partner on AI-based cancer therapies
- Podcast: 'Humans & AI Show',AI-Driven Drug Discovery, Strategic Pivots & Ethical Innovation, with Dr. Gabi Tarcic, Evogene's VP of Product
- Podcast:'Careers in Discovery', with Ofer Haviv, Evogenes' President & CEO
- Molecular farming startup Finally Foods raises $1.2m, strikes deal with CBC Group
- Pharmaphorum – From 0.1% to infinity: How increasingly larger GPT models are transforming the future of drug discovery in the uncharted chemical universe Digital
- Discover Pharma - EXCLUSIVE interview: How foundation models are redefining small molecule drug discovery
- Google Cloud - Evogene: Empowering innovation for life science products, with Google Cloud
- EXCLUSIVE interview: How foundation models are redefining small molecule drug discovery
- BioSpace - Opinion: AI Enables Companies to Break From the Herd in Drug Development
- Opinion: AI Enables Companies to Break From the Herd in Drug Development
- Fierce Biotech - Google Cloud 'can't wait to see what's next' as Servier extends AI drug R&D pact
- Google Cloud 'can't wait to see what's next' as Servier extends AI drug R&D pact
- Evogene: Empowering innovation for life science products, with Google Cloud
- Vegconomist: Finally Foods Secures Funds for AI-Driven Plant Molecular Tech to Produce Casein for Cheese
- Pharmaphorum: The Future of Gut Health. An interview with Biomica's CEO, Dr. Elran Haber
- The Microbiome Times: Evogene and Verb Biotics Enter Collaboration Agreement to Advance Probiotic Innovation
- Aquaculture Magazine: Colors Farm, Evogene and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology
- AgFuder: An insightful op-ed article, by Casterra's CEO, Eyal Ronen, discussing the potential of biofuel crops in alleviating poverty among farmers
- NoCamels news: Casterra helps developing nations fuel vehicles from seed oil
- Renewable Energy Magazine: Casterra announces additional $2.2 million of purchase orders to supply castor seeds for new African territories
- The Times of Israel: Casterra, Evogene subsidiary, nabs $9.1m deal for supply of castor seeds for biofuel production
- AgriBusiness Global: Interview with Lavie Bio's CEO, Amit Noam, on innovations drive the adoption of biological crop protection products and growth stimulants
- AgriTech Tomorrow: The Role of AI and Machine Learning in Advancing Sustainable Biologicals in Agriculture
- Lavie Bio is featured in Start-Up Nation Central’s Q1 2023 Israeli Tech Sector Reports
- Open Access Government: Evogene Ag-Seed Division awarded €1.2m Horizon grant to develop oil-seed crops
- Seed World: Evogene Receives Grant to Develop Oilseed Crops with High CO2 Assimilation
- Ag Tech Talk Podcast: Part 2 of Lavie Bio discussion on the advancement of biologicals
- Ag Tech Talk Podcast: Lavie Bio Uses AI Engine to Save Time and Money Bringing Products to Market (Part 1)
- Seeking Alpha: Evogene Subsidiary Casterra Ag: Castor Seeds Benefiting From Changes In EU Laws
- The Jerusalem Post: Canonic uses AI to breed new line of THC-heavy cannabis products
- The Jerusalem Post: An Israeli perspective on artificial intelligence in 2023
- Forbes article featuring Biomica's $20 Million Funding For AI-Driven Microbiome-Based Therapeutics
- Chemical & Engineering News article
- Ynet News' website: New Israeli technology set to boost wheat yields
- Interview with Dr. Nir Arbel, Evogene’s CPO, on Kan11 English radio: Evogene and the increasing demand for wheat
- Interview: Strategic collaborations accelerate bringing products to market
- Interview with our CEO Ofer Haviv on Bizportal, a leading Israeli financial portal (Hebrew)
- Cantor Fitzgerald Interviews Evogene and its Subsidiaries Biomica and Canonic
- Cantor Fitzgerald Interviews Evogene and its Subsidiaries Lavie Bio and AgPlenus
- Edison TV - Executive interview – Lavie Bio
- Evogene amends its collaboration agreement with Bayer to include genome editing targets
- Phenomics - Growing Together
- Evogene takes gene science to cannabis with AI platform and years of experience
- Interview with Ido Dor in the The Global Biocontrol & Biostimulants E-Newsletter
- Prof. Naama Barkai from Weizmann Institute of Science has been admitted to the Israel Academy of Sciences and Humanities
- Evogene in TheMarker: "Drones in the Air and Sensors in the Ground: How Israeli Farmers Plan to Feed Billions"
- Ag-Biologicals Division of Evogene Joins International Phytobiomes Alliance
- Evogene collaborates with IMAmt on cotton weevils
- Globes - Evogene teams with BASF on insecticides
- Biomica, Evogene's subsidiary, designs molecules to analyze bacteria
- Evogene featured in Channel 2 news story about Israeli agriculture
- Evogene Announce Up to 20% Increased Corn Yield in Trials
- Evogene in Israeli Food Technologies for World Food Day, Israel Ministry of Foreign Affairs
- אבוג'ן הציגה תוצאות חיוביות בפיתוח גן עמיד לפטרייה שפוגעת בבננות
- אבוג'ן תשתף פעולה עם דופונט האמריקאית בשיפור יבול של תירס
- Globes: Evogene and DuPont team to improve corn yields
- Evogene reports progress in corn agreement with Monsanto
- Evogene Ltd. (EVGN) Achieves Important Milestone In Monsanto (MON) Disease Collaboration
- סקירת מסחר
- אבוג’ן השיגה אבן דרך משמעותית בשיתוף הפעולה עם מונסנטו בתחום מחלות צמחים
- אבוג'ן מזנקת 9% ברקע להתקדמות השת"פ עם מונסנטו
- אבוג'ן עולה ב-8% לאחר שהשיגה אבן דרך בשיתוף הפעולה עם מונסנטו
- סקירת מסחר
- אבוג'ן זינקה 10% בוול סטריט: הצליחה בניסוי עם מונסנטו
Events
- BIO International Convention 2026
- 24th Schrödinger European User Group Meeting
- BIO-Europe Spring 2026
- Evogene's CEO to Present at A.G.P.’s Emerging AgBiotech / Bio-Solutions Showcase
- BIO-Europe 2025
- Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York
- BIO 2025 Boston
- AI x FoodTech
- Biomed Israel 2025
- BioEurope Spring
- Evogene's Special General Meeting of Shareholders
- BIO-Europe 2024
- Dr. Ruth Gross, Evogene’s VP of Business Development for Pharma, to attend BIO-Europe 2024
- HLTH 2024 Las Vegas, USA
- Dr. Ruth Gross, Evogene’s VP of Business Development for Pharma, to attend HLTH 2024 in Las Vegas
- BIO Asia-Taiwan 2024
- Dr. Ruth Gross, Evogene's VP of Business Development for Pharma, to attend BIO International Convention 2024
- BIO International Convention 2024
- Dr. Ruth Gross, Evogene's VP Business Development Pharma, to attend Biomed Israel 2024
- Evogene First Quarter 2024 Financial Results, May 23, 2024
- 2024 Annual General Meeting of Shareholders
- Eyal Ronen, Evogene EVP of Business Development, to attend Blue Food Innovation Summit, London
- Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
- CISH Impact Investments Conference (Virtual)
- Biomica's VP R&D, Dr. Shiri Meshner, to present at Pharmabiotic Conference 2024
- Biomica's CEO, Dr. Elran Haber, to attend BIO CEO & Investor Conference
- World Agri-Tech Innovation Summit 2024
- Biomica to participate in the 8th Annual European Microbiome Movement Summit
- Biomica CEO to attend J.P. Morgan Healthcare Week
- World Agri-Tech Innovation Summit, SF, USA
- ROTH Investor Conference
- Evogene Financial Results and Earnings Announcement for the Fourth Quarter and Full Year of 2022
- LD Micro Main Event XV
- Evogene to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- Evogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2022
- World Agri-Tech 2022
- 34th Annual ROTH Investor Conference
- Evogene to Present at Aegis Virtual Conference
- Evogene to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
- H.C. Wainwright Bioconnect Conference
- Evogene to Present at Cantor Virtual Global Healthcare Conference, September 2021
- Evogene to Present at H.C. Wainwright 23rd Annual Global Investment Conference - 2021
- Evogene to Present at Jefferies Virtual Industrials Conference, 2021
- Evogene Financial Results and Earnings Announcement Schedule for the Second Quarter of 2021
- Evogene will participate in Roth Capital Partners Virtual London Conference, to be held on June 21-23, 2021
- Evogene Financial Results and Earnings Announcement Schedule for the First Quarter of 2021
- Biomica To Present at Jefferies Microbiome-Based Therapeutics Summit (Virtual Conference)
- Virtual Investor & Analyst Day - English language event
- Virtual Investor & Analyst Day - Hebrew language event
- AgPlenus and Lavie Bio participate in the Panel Discussion - The Outlook for Crop Protection, to be hosted by Steve Byrne, Ph.D., CFA, BofA US Chemicals Equity Research, being held as part of the Bank of America -Global Ag and Materials Conference on March 4th at 10am EST ( 5pm Israel time)
- Evogene Financial Results and Earnings Announcement for the Fourth Quarter and Full Year of 2020
- Cantor Fitzgerald and Kristen Kluska are hosting Zoom Fireside Chats with Evogene -Fireside Chat #1 – Agriculture Focus Copy
- Cantor Fitzgerald and Kristen Kluska are hosting Zoom Fireside Chats with Evogene -Fireside Chat #2 – Health Focus
- Edison Open House: Global Healthcare 2021
- Evogene to present at Jefferies 2019 Industrials Conference - 7th of August Copy
- Meitav Dash Investment House Hosts Evogene
- Evogene to Present at LD 500 Virtual Conference
- Q1 2020 results – 26th of May, 09:00 EST
- Q2 2019 results - 31st of July, 09:00 EST
- Evogene will release its financial results for the fourth quarter and full year of 2018 on Wednesday, March 13, 2019, Evogene's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time
- Evogene will release its financial results for the fourth quarter and full year of 2017 on Wednesday, February 28, 2018. On the day of the announcement, the Company’s management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time.
- Evogene will release its financial results for the third quarter of 2017 on Wednesday, November 22, 2017
- Evogene to Present at the 26th Asian-Pacific Weed Science Society Conference
- Evogene will release its financial results for the second quarter of 2017 on Thursday, August 10, 2017
Financial Results
- Q1 2026 Consolidated Financial Statements
- Annual Report 2025 – 20-F
- Q4 and Full Year 2025 Consolidated Financial Statements
- Q3 2025 Consolidated Financial Statements
- Q2 2025 Consolidated Financial Statements
- Q1 2025 Consolidated Financial Statements
- Annual report 2024 - 20-F
- Q4 2024 Consolidated Financial Statements
- Q3 2024 Consolidated Financial Statements
- Operating and Financial Review and Prospects_as of_and for the six month ended June 30 2024
- Q2 2024 Consolidated Financial Statements
- Q1 2024 Consolidated Financial Statements
- 2024 Annual General Meeting of Shareholders
- Annual Report 2023 - 20-F
- Q4 and Full Year 2023 Consolidated Financial Statements
- Q3 2023 Consolidated Financial Statements
- Interim Financial Statements and MD&A for the Six Months Ended June 30, 2023
- Q2 2023 Consolidated Financial Statements
- Q1 2023 Consolidated Financial Statements
- Annual report 2022 - 20-F
- Q4 and Full Year 2022 Consolidated Financial Statements
- Q3 2022 Consolidated Financial Statements
- Q2 2022 Consolidated Financial Statements
- Q1 2022 Consolidated Financial Statements
- Annual report 2021 - 20-F
- Q4 2021 Consolidated Financial Statements
- Q3 2021 Consolidated Financial Statements
- Q2 2021 Consolidated Financial Statements
- Q1 2021 Consolidated Financial Statements
- Annual report 2020 - 20-F
- Q3 2020 Consolidated Financial Statements
- Q2 2020 Consolidated Financial Statements
- Q1 2020 Consolidated Financial Statements
- Annual report 2019 - 20-F
- Q4 2019 Consolidated Financial Statements
- Q3 2019 Consolidated Financial Statements
- Q2 2019 Consolidated Financial Statements
- Q1 2019 Consolidated Financial Statements
Calls
- EVGN Q3 2024 Results
- EVGN Q2 2024 Results
- EVGN Q1 2024 Results
- EVGN Q4 2023 Results Transcript
- EVGN Q3 2023 Results Transcript
- EVGN Q2 2023 Results Transcript
- EVGN Q1 2023 Results Transcript
- EVGN Q4 2022 Results Script Transcript
- EVGN Q3 2022 Results Transcript
- EVGN Q2 2022 Results Transcript
- EVGN Q1 2022 Results Transcript
- EVGN Q4 2021 Results Transcript
- EVGN Q3 2021 Results Transcript
- EVGN Q2 2021 Results Script FINAL
- EVGN Q1 2021 Results Script FINAL
- Evogene Full Year and Fourth Quarter 2020 Results Script Final 030321
- EVGN Q3 2020 Results Script FINAL
- EVGN Q2 2020 Results Transcript
- EVGN Q1 2020 Results Script FINAL_Recorded
- EVGN Q4 2019 Results Script Transcript
- EVGN Q3 2019 Results Script FINAL
- EVGN Q2 2019 Results Script Transcript
- EVGN Q1 2019 Results Transcript